Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated MyelofibrosisJean‐Jacques Kiladjian, Bruno Cassinat, Claude Capron et al.|Blood|2018Cited by 26
The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100 × 109/L) at BaselinePaola Guglielmelli, Heinz Gisslinger, Jean‐Jacques Kiladjian et al.|Blood|2020Cited by 7
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY TrialPrithviraj Bose, Nauman Butt, Haris Ali et al.|Journal of Clinical Oncology|2026Cited by 1